Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.
Category: GLP-1 RAs (Drug)
-
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
-
How Much Should Weight Loss Drugs Like Wegovy and Zepbound Cost?
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.
-
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
-
Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
-
PepsiCo Adding Healthier Snacks as Its North American Sales Dip
Rising consumer demand for fewer empty calories is pushing the snack and beverage giant to offer options with less sodium, fat and artificial ingredients.
-
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
-
New Amgen Drug MariTide Shows Promising Weight Loss in Early Data
The drug, which is named MariTide and delivered in a monthly injection, is years from being sold, but caused an average of up to 20 percent weight loss in a small group of patients.